XML 72 R48.htm IDEA: XBRL DOCUMENT v3.20.4
Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Jul. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Collaboration and Other Agreements [Line Items]        
Revenues   $ 104,883 $ 64,188 $ 60,121
I-Mab Biopharma Collaboration And License Agreement | I-Mab        
Collaboration and Other Agreements [Line Items]        
Non-refundable upfront payment $ 15,000      
Potential development and regulatory milestone payments   135,000    
Estimated variable consideration   1,000    
Revenues   2,100 2,300  
Deferred revenue   11,400 13,500  
Deferred revenue, current   4,500 4,400  
Deferred revenue, noncurrent   $ 6,900 $ 9,100  
I-Mab Biopharma Collaboration And License Agreement | I-Mab | Maximum        
Collaboration and Other Agreements [Line Items]        
Potential proceeds from royalties percent 20.00%